James RussellInsomniacs Have More Fun- I Mean, Time #insomnia #insomniac #sleep #sleepingproblems #mentalhealth #bipolar #bipolardisoder
Instead Ask "How Good Was Your Insomnia?" #insomnia #bipolardisoder #bipolarmeme #bipolar #bipolardisorder #sadpim #mentalhealth #insomniamemes
Beetlejuice On Mental Illness #mentalhealth #bipolardisoder #beetlejuiceimpersonator #beetlejuice #beetlejuicebeetlejuicebeetlejuice
Ah yes, feelings. Now I remember why I hate them #bipolardisoder #bipolarmeme #mentalhealthmeme #mentalhealthmemes #memegenerator
Ah yes, feelings. Now I remember why I hate them #bipolardisoder #bipolarmeme #mentalhealthmeme #mentalhealthmemes #memegenerator
PlanetMedicineshttps://pubmed.ncbi.nlm.nih.gov/39214377/ The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trial (Machado-Veira, et al, 2024) #ketamine #fatigue #depression #alcoholusedisorder #bipolardisoder #psychedelic #psychedelics #fda #mentalhealth #psychedelicmentalhealth
The effect of intranasal (R,S)-ketamine on symptoms of fatigue in severe major depressive disorder or bipolar depression with and without comorbid alcohol use disorder: Results from a randomized, double-blind, placebo-controlled trial - PubMed
IN ketamine appears to induce rapid anti-fatigue effects in individuals with severe MDD and BDep both with and without comorbid AUD. This suggests that IN ketamine holds potential as an alternative, rapid-acting, anti-fatigue option for different medical conditions.
https://open-foundation.org/events/online/psilocybin-for-bipolar/?utm_source=newsletter&utm_medium=email&utm_campaign=psilocybin_therapy_for_bipolar_disorder_an_exclusive_q_a_with_rick_strassman&utm_term=2024-04-05 #psychedelics #bipolardisoder #psychedelicresearch #psilocybin
Psilocybin Therapy for Bipolar Disorder
Researchers at Maryland University have completed an early phase clinical trial to asses the feasibility and preliminary outcomes of treating Bipolar II Disorder with single-dose synthetic psilocybin. Specifically, this recently published study treated patients with a BD II diagnosis in a current depressive episode, excluding those in the manic phase of the disorder. The lead researcher Scott Aaronson, and the study's lead therapist, Tammy Miller, will present the study's findings and be available for questions from all of you. This is an excellent opportunity to learn about the world's first psychedelic therapy trial for people with a bipolar disorder, a patient population that is consistently excluded from these trials for fear of inducing new (hypo)manic or psychotic episodes. A novel application indeed!